Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

KIDS

O

OrthoPediatrics Corp. (KIDS)

NGM – Real vaqt narxi. Valyuta: USD

15.52

-0.83 (-5.08%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

15.52

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:10 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Wall Street Analysts Predict a 51.12% Upside in OrthoPediatrics (KIDS): Here's What You Should Know

Wall Street Analysts Predict a 51.12% Upside in OrthoPediatrics (KIDS): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 51.1% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

OrthoPediatrics (KIDS) Upgraded to Buy: What Does It Mean for the Stock?

OrthoPediatrics (KIDS) Upgraded to Buy: What Does It Mean for the Stock?

OrthoPediatrics (KIDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 32.67% Upside in OrthoPediatrics (KIDS): Can the Stock Really Move This High?

Wall Street Analysts See a 32.67% Upside in OrthoPediatrics (KIDS): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 32.7% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

OrthoPediatrics to Participate in Upcoming Conferences

OrthoPediatrics to Participate in Upcoming Conferences

WARSAW, Ind., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that it will participate in two upcoming investor conferences.

OrthoPediatrics Corp. (KIDS) Q4 2025 Earnings Call Transcript

OrthoPediatrics Corp. (KIDS) Q4 2025 Earnings Call Transcript

OrthoPediatrics Corp. (KIDS) Q4 2025 Earnings Call Transcript

OrthoPediatrics (KIDS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

OrthoPediatrics (KIDS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for OrthoPediatrics (KIDS) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) Reports Q4 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.29 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

Record full year 2025 revenue of $236.3 million increased 15% compared to prior year Operating Cash flow improvement of $22 million in full year 2025 Generated $10 million of free cash flow in the fourth quarter, the first quarter of positive free cash flow in Company history WARSAW, Ind., Feb. 26, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the fourth quarter and full year ended December 31, 2025.

OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity

OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity

OrthoPediatrics partner iotaMotion receives FDA clearance for use of its iotaSOFT® cochlear implant insertion system in patients four years and older OrthoPediatrics partner iotaMotion receives FDA clearance for use of its iotaSOFT® cochlear implant insertion system in patients four years and older

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance

Achieves all-time high full year 2025 Revenue of $236.1 million representing growth of 15% over prior year Initiates guidance for record Adjusted EBITDA in 2026

OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Product Launches

OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Product Launches

WARSAW, Ind., Nov. 13, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its OrthoPediatrics Specialty Bracing (“OPSB”) portfolio with two new products launches, the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems. The company now has 31 systems within its OPSB division.